CEPI Provides $16.5 Million for Minapharm's MVA-CR19 Ebola Vaccine to Enter Phase 1 Clinical Trials
CEPI Adds Fourth Technology Platform
The Coalition for Epidemic Preparedness Innovations (CEPI) has allocated up to $16.5 million to Minapharm Pharmaceuticals and Chemical Industries (MIBH) and its German subsidiary ProBioGen AG to advance a filovirus vaccine candidate from preclinical to Phase 1 clinical trials. The candidate, based on the MVA-CR19 platform and not yet branded, is designed to deliver filovirus antigens via the Modified Vaccinia Ankara (MVA) vector to induce both B-cell and T-cell immunity. The Phase 1 trial, planned in Africa, will assess safety and immunogenicity, with the funding supporting preclinical development, process development, and early human testing. This portfolio investment aims to reduce the risk of a public health gap in the event of a single candidate failure, amid a rapid outbreak that has caused over 2,700 deaths.
MVA-CR19's Strength Lies in Production and Broad Immunity
ProBioGen's proprietary MVA-CR19 offers higher infectious titer and lower cell-to-cell dependency in viral release compared to conventional MVA, making it suitable for suspension culture and supernatant-based recovery. The MVA vector can stably express multiple antigens and stimulate both humoral and cellular immunity, providing a strategic advantage by enabling simultaneous comparison of antibody persistence and T-cell responses. ProBioGen will produce the drug substance in Germany, while Minapharm will handle fill and finish in Egypt, with plans to transfer drug substance technology. CEPI's regional manufacturing strategy also aims to establish a complete production system within Africa, beyond clinical success.
Competing Candidates Have Already Entered the Clinical Race
The ChAdOx1 BDBV vaccine from the University of Oxford and Serum Institute of India has entered Phase 1 trials in 50 healthy adults, and Moderna (MRNA)'s mRNA-1469 has also started Phase 1. IAVI's single-dose rVSV-BDBV-GP is considered the most promising candidate by the World Health Organization (WHO), and CEPI has allocated over $60 million to the rVSV, ChAdOx1, and mRNA platforms. As a late entrant, MVA-CR19 must demonstrate competitive advantages in immune response magnitude and duration, production yield, and potential for single-dose administration, beyond initial safety. Platform diversification serves as a risk-mitigation strategy in a scenario where the effectiveness of any single technology in real-world outbreaks remains uncertain.
Approval Markets and Filovirus Gaps Must Be Viewed Separately
Merck & Co. (MRK)'s Ervebo (Ebola Zaire Vaccine Live), an rVSV vaccine targeting the glycoprotein of the Zaire Ebola virus, received conditional approval in the European Union on November 11, 2019, WHO prequalification on November 12, and FDA approval on December 19. Janssen's Zabdeno (Ad26.ZEBOV) and Mvabea (MVA-BN-Filo) two-dose regimen was approved in the European Union in 2020, but neither product has received approval for filovirus indications. WHO has determined that Ervebo's cross-protection evidence is insufficient, and a separate Phase 3 trial using 20,000 doses is ongoing for filovirus. The total Ebola market is estimated at $1.29 billion in 2026, with the vaccine segment reaching $2.42 billion, though actual commercial success will depend more on government, Gavi, and UNICEF stockpiling than private prescriptions.
CEPI's up to $16.5 million funding will cover Minapharm's preclinical, process development, and African Phase 1 clinical costs, but it is not a combination upfront, milestone, and royalty-based technology transfer deal. In the short term, MVA-CR19 is a late entrant compared to the ChAdOx1 BDBV from Oxford and Serum Institute, Moderna (MRNA)'s mRNA-1469, and IAVI's rVSV-BDBV-GP, so the speed of trial initiation and immunogenicity data will determine its valuation. Medium- to long-term opportunities lie in the absence of approved filovirus vaccines and the estimated $2.42 billion Ebola vaccine market in 2026, where it could serve as an alternative for public stockpiling. From a research perspective, it will provide direct comparative evidence on B-cell and T-cell responses, immune durability, and MVA production yield against competing platforms. From an investment standpoint, non-dilutive funding and the strengthening of Egypt's manufacturing base are positive, but it remains a pre-Phase 1 asset, and Ervebo's ongoing Phase 3 filovirus trial could also shift the competitive landscape, making a Watchlist designation appropriate.
Source: FierceBiotech (rss)